Worse outcomes with DEC10-VEN in patients with TP53 mutated AML

Key clinical point: Patients with TP53-mutated acute myeloid leukemia (AML) receiving a 10-day regimen of decitabine with venetoclax (DEC10-VEN) experienced inferior response rates and survival vs those with wild-type TP53 AML.

Major finding: Patients with TP53-mutant vs wild-type TP53 AML had significantly lower overall survival (hazard ratio [HR], 4.67; P < .0001), relapse-free survival (HR, 4.80; P < .001), overall response rate (66% vs 89%; P = .002), and complete response (CR)/CR with incomplete hematologic recovery rate (57% vs 77%; P = .029).

Study details: Findings are from a post hoc analysis of a phase 2 trial including 118 patients with newly diagnosed AML unfit for intensive chemotherapy or with secondary or relapsed/refractory AML receiving frontline therapy with DEC10-VEN. Overall, 35 patients had TP53-mutated AML.

Disclosures: This study was supported by grants from the National Cancer Institute and the National Institutes of Health. Some investigators reported ties with various pharmaceutical companies.

Source: Kim K et al. Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.

Key clinical point: Patients with TP53-mutated acute myeloid leukemia (AML) receiving a 10-day regimen of decitabine with venetoclax (DEC10-VEN) experienced inferior response rates and survival vs those with wild-type TP53 AML.

Major finding: Patients with TP53-mutant vs wild-type TP53 AML had significantly lower overall survival (hazard ratio [HR], 4.67; P < .0001), relapse-free survival (HR, 4.80; P < .001), overall response rate (66% vs 89%; P = .002), and complete response (CR)/CR with incomplete hematologic recovery rate (57% vs 77%; P = .029).

Study details: Findings are from a post hoc analysis of a phase 2 trial including 118 patients with newly diagnosed AML unfit for intensive chemotherapy or with secondary or relapsed/refractory AML receiving frontline therapy with DEC10-VEN. Overall, 35 patients had TP53-mutated AML.

Disclosures: This study was supported by grants from the National Cancer Institute and the National Institutes of Health. Some investigators reported ties with various pharmaceutical companies.

Source: Kim K et al. Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.

Key clinical point: Patients with TP53-mutated acute myeloid leukemia (AML) receiving a 10-day regimen of decitabine with venetoclax (DEC10-VEN) experienced inferior response rates and survival vs those with wild-type TP53 AML.

Major finding: Patients with TP53-mutant vs wild-type TP53 AML had significantly lower overall survival (hazard ratio [HR], 4.67; P < .0001), relapse-free survival (HR, 4.80; P < .001), overall response rate (66% vs 89%; P = .002), and complete response (CR)/CR with incomplete hematologic recovery rate (57% vs 77%; P = .029).

Study details: Findings are from a post hoc analysis of a phase 2 trial including 118 patients with newly diagnosed AML unfit for intensive chemotherapy or with secondary or relapsed/refractory AML receiving frontline therapy with DEC10-VEN. Overall, 35 patients had TP53-mutated AML.

Disclosures: This study was supported by grants from the National Cancer Institute and the National Institutes of Health. Some investigators reported ties with various pharmaceutical companies.

Source: Kim K et al. Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.